Arcutis Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | $0 |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M |
| Operating expenses | — | — | — | $305.3M | $206.5M |
| Cost of revenue | $36.7M | $19.1M | $5.0M | $754,000 | $0 |
| Cash from operations | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M |
| Capital expenditure | $686,000 | $143,000 | $428,000 | $333,000 | $995,000 |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M |
| Total debt | $100.0M | $100.0M | $200.0M | $200.0M | $75.0M |
Shares outstanding 125.1M · Free float 86.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.